From concept, through design, validation, and production across all areas of your business, Pall Biopharmaceuticals can help you to adapt to changing market conditions with innovative solutions. Whether that means developing a process for a new drug quickly, validating consistent results, ensuring quality control, delivering data, or making processing easier, faster, and better, Pall is ready to address your needs with intuitive technologies.  

Biopharmaceutical Capabilities

Our portfolio of products and services is one of the most comprehensive in the industry, with intuitive technologies that customers can rely on, so they can focus on innovating for the future. 

  • Cell Culture

    Pall's Allegro™ single use cell culture technologies are complete solutions that make your total upstream process robust and efficient, from R&D to full production scale.

    Learn More »
  • Chromatography

    Cost-effective and innovative chromatographic purification platforms for today’s demanding applications and productivity goals.

    Learn More »
  • Continuous Processing

    Breakthrough technologies that enable integrated, process-scale continuous production of biotherapies in single-use formats.

    Learn More »
  • Depth Filtration

    Pall's high performance depth filtration solutions are the best choice for cell harvest, clarification, and prefiltration process steps.

    Learn More »
  • Filling Technologies

    Flexible single-use technologies protect your product at a critical manufacturing stage.

    Learn More »
  • Filtration

    An unmatched portfolio of traditional and single-use products with custom service support from R&D to clinical phases to production.

    Learn More »
  • Single-Use Solutions

    Single-use solutions that allow easy scale-up from the lab to full cGMP commercial production.

    Learn More »
  • Tangential Flow Filtration

    Pall's line of scalable TFF products range from single-use modules to cleanable cassettes, and from standard lab and benchtop systems to fully customizable process systems.

    Learn More »
  • Viral Clearance

    A range of filters and filter capsules optimized to provide robust, economic solutions for virus removal whatever your process requirements.

    Learn More »

Latest Products

Learn about the latest cutting-edge Pall® products and innovative technologies to help improve, accelerate and optimize your processing steps.
Learn about the latest cutting-edge Pall® products and innovative technologies to help improve, accelerate and optimize your processing steps.
Read more

INDUSTRY-LEADING PRODUCTS, SERVICES AND SUPPORT
Allegro™ MVP Single-Use System

Allegro™ MVP Single-Use System

A fully automated bioprocessing system, providing flexibility and improved productivity in upstream and downstream single-use processing.  Single-use technology continues to be adopted across many areas of bioprocessing. The use of automation provides additional benefits in manufacture such as consistency in product quality, reduced labor costs and reduction of operator errors.

Single-Use Solutions

Biomanufacturers need suppliers as innovative as they are.  Our unique single-use platform provides a comprehensive range of disposable process solutions from upstream, through downstream to formulation and filling. 

We have developed a unique approach, keeping the same materials of construction to allow easy scale-up from lab scale to full cGMP commercial operation, with the capability to provide the same robustness, reliability and batch records that you require to produce your drugs.

Biomanufacturers need suppliers as innovative as they are.  Our unique single-use platform provides a comprehensive range of disposable process solutions from upstream, through downstream to formulation and filling. 

We have developed a unique approach, keeping the same materials of construction to allow easy scale-up from lab scale to full cGMP commercial operation, with the capability to provide the same robustness, reliability and batch records that you require to produce your drugs.

We can serve our customers globally with strong technical support and a very robust and reliable supply chain with our global manufacturing platform meeting all the necessary quality requirements. We pride ourselves on the strong quality by design and ease-of-use attributes that we put into all our Allegro single-use systems, thus allowing our end users to meet consistently all the appropriate safety and regulatory requirements.    

We can serve our customers globally with strong technical support and a very robust and reliable supply chain with our global manufacturing platform meeting all the necessary quality requirements. We pride ourselves on the strong quality by design and ease-of-use attributes that we put into all our Allegro single-use systems, thus allowing our end users to meet consistently all the appropriate safety and regulatory requirements.    

Kleenpak® Presto Sterile Connector

Kleenpak® Presto Sterile Connector

Genderless sterile connections - Intuitive, reliable, secure.  The Kleenpak Presto sterile connector is the next generation in the Allegro™ range of single-use fluid handling and management devices. This new genderless connection allows for the permanent sterile connection of two fluid streams for a large range of biopharmaceutical applications.

INDUSTRY-LEADING PRODUCTS, SERVICES AND SUPPORT
Allegro™ Unison hMSCs and Media

Allegro™ Unison hMSCs and Media

Allegro Unison human mesenchymal stem cells (hMSCs) and media facilitate large scale hMSC expansion and accelerate cell therapy and regenerative medicine development. 

Cell Culture

Complete solutions to make your total upstream process robust and efficient, from R&D to full production scale, whether you are growing adherent cells for cell therapy or vaccine applications, or have large volume suspension cell culture requirements.

Complete solutions to make your total upstream process robust and efficient, from R&D to full production scale, whether you are growing adherent cells for cell therapy or vaccine applications, or have large volume suspension cell culture requirements.

Webinar: Thursday, April 27

Design, Characterization, and Scale-Up Strategy for a New Single-Use Production-Scale Bioreactor

Learn about the design, characterization and scale-up strategy for a new bioreactor and how it brings significant advantages to the upstream process for handling and process assurance, while maintaining optimal cell culture performance.

Design, Characterization, and Scale-Up Strategy for a New Single-Use Production-Scale Bioreactor

Learn about the design, characterization and scale-up strategy for a new bioreactor and how it brings significant advantages to the upstream process for handling and process assurance, while maintaining optimal cell culture performance.

Events and Webinars

Stay informed on the latest industry topics and trends, and be notified first of a range of innovations and solutions to continuously improve your processes. Click “Learn More” to subscribe to regular email updates.
Stay informed on the latest industry topics and trends, and be notified first of a range of innovations and solutions to continuously improve your processes. Click “Learn More” to subscribe to regular email updates.
Read more

International Society for Cellular Therapy Annual Meeting 2017

Product Theatre Presentation:

May 4: 13:00 – 13:30

 

Human mesenchymal stem cells (hMSC) represent the most highly utilized cell type for cell therapy and regenerative medicine applications. However, a major impediment to progress in the field is availability of sufficient numbers of high quality hMSC for process development studies. Given that large numbers of high quality cells are required for many applications and that large surface area requirement for cell expansion is necessary, a search for a practical manufacturing platform for hMSC expansion has been ongoing over the last decade.

We have developed a manufacturing platform that enables reproducible expansion of large numbers of high quality hMSC from fed-batch microcarrier cultures without the need for media exchanges or extensive process development. Expansion data generated with bone marrow derived hMSC using sterile microcarriers in single-use bioreactors reproducibly generated over twenty-fold expansion in 4 days. Cryopreserved hMSC seeded directly onto microcarriers in the PadReactor Mini bioreactor followed by transfer to a larger volume PadReactor System showed >200-fold expansion in only 8 days. Cells expanded using this platform and processes maintain critical quality and functional parameters. This single-use system and associated process can be used by others to generate billions of cells without the need for further development studies.

Presenter: Mark Szczypka - Senior Director, Single-Use Technologies, Process Development and Applications R&D, Scientific and Laboratory Services

 

Scientific Poster Presentations:
May 4: 17:00 - 18:30, Poster Session # 1 – Exhibit Hall

 

  • Development and Optimization of Large Scale Production of Adenoviral Vector and Autologous Insulin-Producing Cells Using iCELLis® 500 and Xpansion® 200 Single-Use Bioreactors
  • Industrialization of AdenoVirus Production and Purification with the iCELLis 500 Single-use Bioreactor
  • Rapid and Robust Large-Scale Expansion of High Quality Human Mesenchymal Stem Cells for Use in Regenerative Medicine Applications
  • Simple and Efficient Cell Harvest Methods for Microcarrier cultures in Bioreactors

Presenter: Mark Szczypka - Senior Director, Single-Use Technologies, Process Development and Applications R&D, Scientific and Laboratory Services



Presentation:
May 5: 15:30 – 17:00, Early Stage Professionals (ESP) Session 1 – Advanced Strategic Innovations for Cell & Gene Therapies



The focus of this session will be scientific innovation, presented by early stage professionals. The session will be wide ranging, with topics about manufacturing the world's largest therapeutic cell bank to CAR-T cells and viral vector engineering for transgene delivery. At the end of this session, participants should be able to identify what current advances are being made with CAR T cells, What options are available to scale up UC-MSCs, and recent approaches to engineering vector-based transgene delivery.

Presenter: Ben Weil, MRes, EngD, University College London

 

Pall® Products Featured:

Learn More

Design, Characterization, and Scale-Up Strategy for a New Single-Use Production-Scale Bioreactor

What Will I Learn:

 

- Why a square cross-section brings significant advantages to the upstream process, for handling, process assurance, while maintaining optimal cell culture performance

- About the performance of a square-shaped bioreactor, in terms of mixing efficiency, mass transfer of oxygen (kLa), and CO2 stripping

- About applying system engineering principles toward bioreactor characterization, and how tech transfer methods are leveraged across designs, from the bench to production vessels

 

Learn More about this webinar

Watch

About Pall Biopharmaceuticals

Pall products have played key development and manufacturing roles in life saving drugs that range from Ebola vaccines to cancer-curing monoclonal antibodies. Cutting-edge research demands high quality products that combine industry-leading effectiveness with high performance to increase profitability without sacrificing safety.

 

Our portfolio of products fit into integrated systems that reduce total cost of ownership by improving process economics. Reducing total cost of ownership is possible when customers partner with a supplier who is in tune with their unique challenges, whether for clinical or full manufacturing scale. Pall provides complete coverage from cell culture to formulation and filling. Our biopharmaceutical portfolio helps create life improving drugs faster and with lower upfront costs.

 

Just like the pharmaceutical industry, Pall continues to innovate. For example, our continuous processing technologies enable truly continuous production steps. Award-winning critical downstream processing (DSP) products like the Cadence Inline Concentrator (ILC) enables continuous concentration of the product, reducing shear damage and processing time and improving quality. Our disruptive Cadence Acoustic Separator in conjunction with a polishing depth filter will continuously remove cells and cell debris from cell culture in a closed system, without the need for centrifugation or primary depth filtration.  It reduces depth filtration and buffer use, and provides consistent solids reduction.

 

We will continue to evolve as the market changes. The rise of single-use facilities, process intensification, integrated unit operations, and continuous processing is improving facility efficiency and flexibility while simultaneously reducing footprint and processing times. Pall has the only bioprocessing portfolio on the market that can support biopharmaceutical manufacturers from upstream to downstream and into the final filling and finish phases. This single use, multiple solutions, outlook is an end-to-end solution for biomanufacturers seeking fully validated solutions and guaranteed scalable supply chain security.

 

No matter where your team is, Pall is there to support them. Pall Scientific and Laboratory Services have more than 30 years of experience with validation in the pharmaceutical industry. Global ISO9001 certified Centers of Excellence (CoE) are available to streamline scientific development and scale up.

ASK BIOPHARMACEUTICALS A QUESTION

Choose Industry
  • Aerospace
  • Biopharmaceuticals
  • Chemicals & Polymers
  • Food & Beverage
  • Industrial Manufacturing
  • Laboratory
  • Medical
  • Microelectronics
  • Oil & Gas
  • Pall
  • Power & Utilities
Choose Support Type
  • Customer Service
  • General Inquiry
  • Quality Assurance
  • Tech Support

Thank you for your inquiry.

Your inquiry has been received and will be reviewed by a Pall representative.